Welcome to our dedicated page for Rhythm Pharmaceu news (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceu stock.
Rhythm Pharmaceuticals, Inc. develops and commercializes therapies for rare neuroendocrine diseases, centered on IMCIVREE (setmelanotide), an MC4R agonist for hyperphagia and severe obesity linked to rare MC4R pathway disorders. Company updates commonly cover U.S. and international commercialization of setmelanotide, regulatory authorizations and label expansions for acquired hypothalamic obesity, Bardet-Biedl syndrome, POMC/PCSK1 deficiency and LEPR deficiency, and safety information tied to approved uses.
Rhythm news also follows clinical data from setmelanotide studies, including acquired hypothalamic obesity and genetically caused MC4R pathway diseases, along with development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism. Recurring corporate items include financial results, specialty-pharmacy access arrangements, healthcare conference presentations and board governance changes.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced publication of a new, evidence-based diagnostic algorithm for Bardet-Biedl syndrome (BBS) in the American Journal of Medical Genetics. Developed by international experts and patient groups, the algorithm integrates updated clinical and genetic insights to support earlier, clinically based BBS diagnosis across all ages and presentations.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced management participation in two upcoming healthcare investor conferences. CFO Hunter Smith will join a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 12:50 p.m. ET.
CEO David Meeker will speak at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, at 1:20 p.m. ET. Both webcasts and 30-day replays will be accessible via the company’s Investor Relations webpage under “Events & Presentations”.
Rhythm Pharmaceuticals (Nasdaq:RYTM) will present six posters, including four with new data, on setmelanotide at the 2026 European Congress of Endocrinology in Prague.
Highlights include real-world BMI reductions in acquired hypothalamic obesity, Phase 3 cardiometabolic index improvements, underrecognized hyperphagia in Bardet-Biedl syndrome, and the lifelong burden of acquired hypothalamic obesity after craniopharyngioma.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that David Meeker, M.D., Chairman, President and CEO, will participate in a fireside chat at the Bank of America Global Healthcare Conference on May 13, 2026 at 3:00 p.m. PT in Las Vegas.
The event will be webcast and available under Events & Presentations in the company Investor Relations site, with a replay available on the Rhythm website for 30 days.
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 2026 results and a business update on May 5, 2026. IMCIVREE generated $60.1M in global net product revenue; U.S. sales were $36.9M (61%) and international sales $23.2M (39%). FDA approved IMCIVREE for acquired hypothalamic obesity on March 19, 2026; European Commission authorized marketing for acquired HO; Japanese review is underway. Cash and short-term investments were $340.6M as of March 31, 2026. Non-GAAP operating expense guidance for 2026 is $385M–$415M.
Rhythm Pharmaceuticals (Nasdaq: RYTM) reported new pediatric data presented at the Pediatric Endocrine Society, showing longer-term setmelanotide outcomes in acquired hypothalamic obesity.
Highlights: in 10 pediatric patients completing 2.5 years, mean changes from baseline were BMI -16.4%, BMI Z-score -1.6, and %BMI95 -34.2 percentage points. Phase 3 TRANSCEND pediatric data after 1 year showed 71.1% improved ≥1 weight category.
Rhythm Pharmaceuticals (NASDAQ: RYTM) announced the European Commission authorized IMCIVREE (setmelanotide) for treatment of obesity and control of hunger in adults and children aged 4+ with acquired hypothalamic obesity.
The approval cites the Phase 3 TRANSCEND pivotal cohort (n=120): a statistically significant placebo-adjusted BMI reduction of -19.8%, with setmelanotide showing -16.5% mean BMI change versus +3.3% for placebo at 52 weeks (p<0.0001). Adult and pediatric subgroup placebo-adjusted BMI reductions were -19.2% and -20.2%, respectively. Common adverse events (>20%) included nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation and headache. Commercial launches are anticipated in 2027; the U.S. sNDA was approved March 19, 2026.
Rhythm Pharmaceuticals (Nasdaq: RYTM) will report first quarter 2026 financial results on Tuesday, May 5, 2026 with a live conference call and webcast at 8:00 a.m. ET. The company also announced a fireside chat by CFO Hunter Smith at the Needham Virtual Healthcare Conference on April 16, 2026 at 11:00 a.m. ET.
Live webcasts for both events will be available in the Investor Relations "Events and Presentations" section at the company's investor website, with archived replays available approximately two hours after the earnings call and for 30 days after each event.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced Board changes on April 3, 2026: Kim Popovits was appointed director and Ed Mathers will depart.
Kim brings more than 40 years of life‑sciences leadership, including CEO and chairman roles at Genomic Health and senior commercialization roles at Genentech. Ed served on the Board since 2013.
Rhythm Pharmaceuticals (Nasdaq: RYTM) announced a positive CHMP opinion recommending expansion of IMCIVREE® (setmelanotide) to treat obesity and control hunger in adults and children aged 4+ with acquired hypothalamic obesity due to hypothalamic injury or impairment.
A final European Commission decision is anticipated in the second quarter of 2026; the CHMP opinion follows an FDA approval announced last week.